Payment overview · 2025
General Payments
$186,839.05
441 reported records · 16 companies
Healthcare provider profile · identity verified
Vikram Mehra, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · KATY, TX · NPI 1801848957
Verified facts
What the public records show
CMS Open Payments records show Vikram Mehra, M.D. received $186,839.05 in general payments during 2025 across 441 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 41.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Aristada, Austedo Xr, Auvelity, Fanapt, Ingrezza, Invega Sustenna, Lybalvi, Rexulti, Trintellix.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Aristada by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Lybalvi by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Auvelity by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Invega Sustenna by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rexulti by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trintellix by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Austedo Xr by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $77,971.09 | 41.7% | 154 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $54,706.96 | 29.3% | 95 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $40,520.37 | 21.7% | 74 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $10,660.16 | 5.7% | 44 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $1,620.00 | 0.9% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $331.80 | 0.2% | 15 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $287.48 | 0.1% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $259.15 | 0.1% | 18 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $137.61 | 0.1% | 6 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $110.21 | 0.1% | 4 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $82.28 | 0.0% | 6 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $45.04 | 0.0% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $36.27 | 0.0% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.93 | 0.0% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $23.00 | 0.0% | 1 | 2025 |
| Luye Pharma (USA) Ltd. | Unresolved — no canonical attribution shown | $19.70 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $145,929.50 | 56 |
| Consulting Fee | $17,705.00 | 7 |
| Travel and Lodging | $15,161.96 | 151 |
| Food and Beverage | $7,967.09 | 226 |
| Education | $75.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $69,806.09 | 151 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $54,706.96 | 95 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $29,376.71 | 39 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $11,068.16 | 34 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $10,791.70 | 49 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Lundbeck LLC, Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,626.07 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $482.07 | 24 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $331.80 | 15 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $287.48 | 17 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $259.15 | 18 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $85.92 | 3 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $82.28 | 6 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $45.04 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $36.27 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $27.93 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA Normalized: invega |
Drug | Janssen Pharmaceuticals, Inc | $24.29 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| ERZOFRI EXTENDED-RELEASE Normalized: erzofri extended release |
Drug | Luye Pharma (USA) Ltd. | $19.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ARISTADA aristada |
2025 | Aristada | 2024 | 98 | exact normalized | Medicare Part D |
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Auvelity auvelity |
2025 | Auvelity | 2024 | 41 | exact normalized | Medicare Part D |
| FANAPT fanapt |
2025 | Fanapt | 2024 | 18 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 31 | exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 139 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 45 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
98 | 51 |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
139 | 60 |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
41 | 14 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
31 | 13 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
45 | 17 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
45 | 17 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
45 | 17 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
18 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Diazepam | Diazepam | 234 | 93 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 215 | 43 |
| Trazodone Hcl | Trazodone Hcl | 185 | 70 |
| Duloxetine Hcl | Duloxetine Hcl | 168 | 67 |
| Clonazepam | Clonazepam | 163 | 56 |
| Alprazolam | Alprazolam | 151 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 145 | 57 |
| Lybalvi | Olanzapine/Samidorphan Malate | 139 | 60 |
| Fluoxetine Hcl | Fluoxetine Hcl | 108 | 31 |
| Gabapentin | Gabapentin | 105 | 45 |
| Quetiapine Fumarate | Quetiapine Fumarate | 102 | 44 |
| Lorazepam | Lorazepam | 99 | 29 |
| Aristada | Aripiprazole Lauroxil | 98 | 51 |
| Bupropion Xl | Bupropion Hcl | 78 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 74 | 25 |
| Lithium Carbonate | Lithium Carbonate | 69 | 36 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 66 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 31 |
| Clozapine | Clozapine | 60 | suppressed |
| Memantine Hcl | Memantine Hcl | 58 | 25 |
| Mirtazapine | Mirtazapine | 57 | 19 |
| Lamotrigine | Lamotrigine | 53 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 24 |
| Methylphenidate Hcl | Methylphenidate Hcl | 46 | 13 |
| Rexulti | Brexpiprazole | 45 | 17 |
| Oxcarbazepine | Oxcarbazepine | 42 | 15 |
| Sertraline Hcl | Sertraline Hcl | 42 | 23 |
| Auvelity | Dextromethorphan Hbr/Bupropion | 41 | 14 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 38 | 16 |
| Benztropine Mesylate | Benztropine Mesylate | 37 | 18 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 36 | 18 |
| Olanzapine | Olanzapine | 34 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 33 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | 12 |
| Invega Sustenna | Paliperidone Palmitate | 31 | 13 |
| Prazosin Hcl | Prazosin Hcl | 31 | 16 |
| Lurasidone Hcl | Lurasidone Hcl | 29 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | 13 |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Modafinil | Modafinil | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 19 | suppressed |
| Fanapt | Iloperidone | 18 | 12 |
| Adderall Xr | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Austedo Xr | Deutetrabenazine | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Ingrezza | Valbenazine Tosylate | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $186,839.05 · 441 records | E.R. Squibb & Sons, L.L.C. | ABILIFY ASIMTUFII, ARISTADA, AUSTEDO XR, Auvelity, Azstarys, CAPLYTA, COBENFY, ERZOFRI EXTENDED-RELEASE, FANAPT, INGREZZA, INVEGA, INVEGA SUSTENNA, LOREEV XR, LYBALVI, REXULTI, TRINTELLIX, UZEDY, VRAYLAR | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Aristada play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Alkermes, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error